DK0668781T3 - Lymfokingenterapi af cancer i kombination med tumorantigener - Google Patents

Lymfokingenterapi af cancer i kombination med tumorantigener

Info

Publication number
DK0668781T3
DK0668781T3 DK92922731T DK92922731T DK0668781T3 DK 0668781 T3 DK0668781 T3 DK 0668781T3 DK 92922731 T DK92922731 T DK 92922731T DK 92922731 T DK92922731 T DK 92922731T DK 0668781 T3 DK0668781 T3 DK 0668781T3
Authority
DK
Denmark
Prior art keywords
tumor
site
tumor antigens
patient
cancer
Prior art date
Application number
DK92922731T
Other languages
English (en)
Inventor
Robert E Sobol
H Gage Fred
Ivor Royston
Theodore Friedman
Habib Fakhrai
Original Assignee
Sidney Kimmel Cancer Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27119842&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0668781(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sidney Kimmel Cancer Ct filed Critical Sidney Kimmel Cancer Ct
Application granted granted Critical
Publication of DK0668781T3 publication Critical patent/DK0668781T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK92922731T 1991-10-25 1992-10-23 Lymfokingenterapi af cancer i kombination med tumorantigener DK0668781T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78135691A 1991-10-25 1991-10-25
US86364192A 1992-04-03 1992-04-03
PCT/US1992/008999 WO1993007906A1 (en) 1991-10-25 1992-10-23 Lymphokine gene therapy of cancer

Publications (1)

Publication Number Publication Date
DK0668781T3 true DK0668781T3 (da) 2000-04-17

Family

ID=27119842

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92922731T DK0668781T3 (da) 1991-10-25 1992-10-23 Lymfokingenterapi af cancer i kombination med tumorantigener

Country Status (9)

Country Link
EP (1) EP0668781B1 (da)
JP (1) JP3524918B2 (da)
AT (1) ATE188125T1 (da)
CA (1) CA2121127A1 (da)
DE (1) DE69230506T2 (da)
DK (1) DK0668781T3 (da)
ES (1) ES2144426T3 (da)
GR (1) GR3032660T3 (da)
WO (1) WO1993007906A1 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662896A (en) 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US6569679B1 (en) 1988-03-21 2003-05-27 Chiron Corporation Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene
US6133029A (en) 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
US6241982B1 (en) 1988-03-21 2001-06-05 Chiron Corporation Method for treating brain cancer with a conditionally lethal gene
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
FR2710536B1 (fr) * 1993-09-29 1995-12-22 Transgene Sa Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire.
JPH09503920A (ja) 1993-11-18 1997-04-22 チロン ビアジーン，インコーポレイティド 条件致死遺伝子を利用する組成物及び方法
FR2713657B1 (fr) * 1993-12-13 1996-03-01 Transgene Sa Nouveaux vecteurs pour le traitement du sida.
CA2178950A1 (en) * 1993-12-14 1995-06-22 Yajun Guo Tumor cell fusions and methods for use of such tumor cell fusions
DE4406073A1 (de) * 1994-02-24 1995-08-31 Univ Ludwigs Albert Verfahren zur Herstellung von humanen, klonogenen Fibroblasten, Verfahren zur Gentransfizierung von Fibroblasten und so erhaltene Fibroblasten
US5759535A (en) * 1994-05-13 1998-06-02 Research Corporation Technologies, Inc. Immunotherapeutic strategies for the treatment of cancer
US5772995A (en) * 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
JP3822261B2 (ja) * 1994-09-09 2006-09-13 財団法人癌研究会 癌の遺伝子治療剤
WO1996013275A1 (en) * 1994-10-31 1996-05-09 Tkb Associates Limited Partnership Methods and products for enhancing immune responses
DE69627644T2 (de) * 1995-03-09 2004-02-19 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Vektoren, die therapeutische gene fuer antimikrobielle peptide enthalten, zur verwendung in der gentherapie
FR2746109B1 (fr) 1996-03-12 1998-04-17 Rhone Poulenc Rorer Sa Milieu pour la conservation de materiel biologique
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
EP0834323A1 (en) * 1996-09-30 1998-04-08 Introgene B.V. Cytokine gene therapy for treatment of malignacies
JP2001522226A (ja) 1997-01-31 2001-11-13 リサーチ コーポレイション テクノロジーズ インコーポレイテッド セミ−同種異系細胞での癌の免疫療法
KR20010074426A (ko) 1998-02-02 2001-08-04 추후제출 만능 면역조절 사이토킨-발현 방관자 세포주 및 관련조성물 및 제조방법 및 사용방법
US6342216B1 (en) * 1999-03-17 2002-01-29 The Board Of Regents, The University Of Texas System Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
US7101543B2 (en) 2000-03-31 2006-09-05 Novarx Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells
AU2001253031A1 (en) * 2000-03-31 2001-10-15 Novarx Compositions containing genetically modified lung cancer cells expressing a tgf-beta inhibitor
AU2001266669A1 (en) 2000-05-31 2001-12-11 Board Of Regents, The University Of Texas System Adjuvant preparation for the induction of specific immunity
WO2005067981A1 (ja) * 2004-01-13 2005-07-28 Dnavec Research Inc. 免疫刺激性サイトカインをコードするマイナス鎖rnaウイルスベクターを用いる腫瘍の遺伝子治療
WO2006105255A2 (en) 2005-03-29 2006-10-05 The Board Of Trustees Of The University Of Illinois Cancer vaccines and therapeutic methods
US20220401541A1 (en) * 2019-11-02 2022-12-22 Figene, Llc Intratumoral administration of immune cellular therapeutics

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06501161A (ja) * 1990-09-14 1994-02-10 ザ　ジョーンズ　ホプキンス　ユニバーシティー 抗腫瘍免疫性の強化と遺伝子治療のための組成物及び方法

Also Published As

Publication number Publication date
GR3032660T3 (en) 2000-06-30
JPH07503455A (ja) 1995-04-13
DE69230506D1 (de) 2000-02-03
JP3524918B2 (ja) 2004-05-10
EP0668781A4 (en) 1995-06-14
WO1993007906A1 (en) 1993-04-29
DE69230506T2 (de) 2000-06-21
ATE188125T1 (de) 2000-01-15
ES2144426T3 (es) 2000-06-16
EP0668781B1 (en) 1999-12-29
EP0668781A1 (en) 1995-08-30
CA2121127A1 (en) 1993-04-29

Similar Documents

Publication Publication Date Title
DK0668781T3 (da) Lymfokingenterapi af cancer i kombination med tumorantigener
SG46445A1 (en) Vaccines against cancer and infectious diseases
CA2267157A1 (en) Cancer immunotherapy using tumor cells combined with mixed lymphocytes
DK0504177T3 (da) IL-11, et pattedyrcytokin
IL98957A (en) Antigen-specific cytotoxic lymphocytes obtained by culture with IL-7 without stimulation by an antigen or mitogen
IL87621A0 (en) Conjugates of cytokines with immunoglobulins,their preparation and pharmaceutical compositions containing them
DE69632261D1 (de) Krebs und infektiöse krankheiten immuntherapie unter anwendung von antigen -präsentierenden zellen sensibilisiert mit hitzeschock - protein - antigen - komplexen
FI924069A0 (fi) Terapeutiskt anvaendbara peptider och peptidfragment.
DE69433013D1 (de) Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
NZ309659A (en) Composition comprising LbeIF4A and/or LmeIF4A polypeptides (Leishmania antigen) and methods for enhancing immune responses
EP0202642A3 (en) Process for the in vitro immunization of human splenocytes against tumor associated antigens
IL92009A0 (en) Cell lines,monoclonal anti-bodies and pharmaceutical compositions containing the same
NO930798L (no) Fremgangsmaate og middel mot tumorer
ATE385809T1 (de) Saponin-zusammensetzungen und deren verwendung
Stoeck et al. In vitro expansion and analysis of T lymphocyte microcultures obtained from the vaccination sites of cancer patients undergoing active specific immunization with autologous Newcastle-disease-virus-modified tumour cells
Yu et al. The humoral antitumor responses induced by IL-4 gene-modified tumor vaccine
Suzuki et al. A Pathogenic Role of Th2 Cells and Their
MD1682F1 (en) Method of immunotherapy in lingering pneumonias to children
NO920160L (no) Cytokin- og hormonbaerere for konjugatvaksiner
IE861358L (en) Process for the in vitro immunization of human splenocytes¹against tumor associated antigens